Main Article Content
Objectives: To analyse the adverse drug reactions (ADR) and related economic burden on the health care system and health seekers
Methods: A prospective observational study was conducted in a South Indian tertiary care teaching hospital from July 2016 – December 2018.ADRs were analyzed for their causality, severity, predictability, and preventability through standard scales and were reported to the Pharmacovigilance Program of India (PvPI) through a specified updated Indian Pharmacopoeia Commission (IPC) suspected ADR reporting form. The total cost burden including both direct and indirect were calculated by assessing the ADR management including the clinical investigations done. The indirect cost was calculated based on the per capita analysis by using the Gross Domestic Product (GDP) of our study area.
Results: Among 458 ADRs, 81.88% were reported in Adult population with an almost same incidence in both the genders, majority were probable (41.70%) and Antibiotics were most commonly involved (16.18%). Around 60% ADRs were treated with at least one drug, 27% ADRs required either hospitalization or increased length of Hospitalization. A total of 989164.5 Indian Rupee (INR) was spent by the hospital and the patients for the management of ADRs, of which 79% was direct cost and 21% was indirect cost.
Conclusion: In this hospital, 26.88% of patients were identified with ADRs that were associated with high direct costs, due to hospitalization/extended hospitalizations, which resulted in an extra economic burden to the healthcare sector and seekers for the management of ADRs.
Sivasankaran P, Gupta M, Satyanarayan RB, Raja D. Pattern of Adverse Drug Reactions in a Govt. District Headquarters Hospital in Tamilnadu, India. Ind J of Pharm Prac. 2016;9(1):33–36.
Ribeiro-Vaz I, Silva A, Costa Santos C, Correia RC. How to promote adverse drug reaction reports using information systems – a systematic review and meta-analysis. BMC Med Inform DecisMak. 2016;16(27). Available:https://doi.org/10.1186/s12911-016-0265-8.
Lobo MGAA, Sandra MBP, José GDC, Valéria GM, Pranchevicius MCS. Adverse drug reaction monitoring: support for pharmacovigilance at a tertiary care hospital in Northern Brazil. BMC PharmacolToxicol. 2013;14(5). Available:https://doi.org/10.1186/2050-6511-14-5
Saqib A, Sarwar MR, Sarfraj M, Iftikhar S. Causality and preventability assessment of adverse drug events of antibiotics among inpatients having different lengths of hospital stay: a multicenter, cross-sectional study in Lahore, Pakistan. BMC PharmacolToxicol. 2018;19(34). Available:https://doi.org/10.1186/s40360-018-0222-5.
Lucca JM, Varghese NA, Ramesh M, Ram D. Economic impact and severity of adverse drug reactions in patients with mental illness: A prospective observational study. Int J Health Allied Sci. 2017;6(2):93-8. Available:http://doi.10.4103/ijhas.IJHAS_191_15.
Rajeshreddy SGSV, Lokesh V. Patil. Causality assessment and the severity of the adverse drug reactions in tertiary care hospital: a pharmacovigilance study. Int J Basic ClinPharmacol 2017;6(12):2800- 03.
Rasool S, Nazeer M, Majeed M. Assessment of causality and severity of various reported adverse drug reactions by different classes of anti-cancer drugs. Int J Basic ClinPharmacol. 2018(7):503-10. Available:http://dx.doi.org/10.18203/2319-2003.ijbcp20180665.
Akhideno PE, Fasipe OJ, Isah AO, Owhin OS. Economic burden, impact, and consequence of adverse drug reactions among medical inpatients in clinical practice. J Clin Sci. 2018;15(4):186- 93. Available:http://doi.10.4103/jcls.jcls_64_18.
Chen Wu, Chaim M. Bell, Walter P. Wodchis. Incidence and Economic Burden of Adverse Drug Reactions among Elderly Patients in Ontario Emergency Departments A Retrospective Study. Drug Saf. 2012;35(9):769-81.
R J Lihite, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, et al. A study on adverse drug reactions in a tertiary care hospital of Northeast India. Alex J of Med 2017;53(2):151–56. Available:http://dx.doi.org/10.1016/j.ajme.2016.05.007.
Vázquez-Alvarez AO, Brennan-Bourdon LM, Rincón-Sánchez AR, Islas-Carbajal MC, Huerta-Olvera SG. Improved drug safety through intensive pharmacovigilance in hospitalized pediatric Available:patients. BMC PharmacolToxicol. 2017;18(1):79. Available:http://doi:10.1186/s40360-017-0186-x, PMID: 29216902
Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study.BMCClinPharmacol. 2007;7(8). Available:http:// doi:10.1186/1472-6904-7-8
De Almeida SM, Romualdo A, Ferraresi A de A, Zelezoglo GR, Alexandre R. Marra, Michael B. Edmond. Use of a trigger tool to detect adverse drug reactions in an emergency department.BMCPharmacolToxicol. 2017;18:71. Available:http://doi:10.1186/s40360-017-0177-y.
Hakkarainen KM, Hedna K, Petzold M, Staffan H. Percentage of Patients with Preventable Adverse Drug Reactions and Preventability of Adverse Drug Reactions – A Meta-Analysis. Plos One. 2012;7(3):e33236. Available:http://doi:10.1371/journal.pone.0033236. PMID: 22438900
R Bordet, S Gautier, H Le Louet, B Dupuis. Analysis of the direct cost of adverse drug reactions in hospitalized patients. Eur J ClinPharmacol. 2001;56(12):935-41. DOI: 10.1007/s002280000260.
Guidance Document for Spontaneous Adverse Drug Reaction Reporting Version: 1.0. Published by Indian Pharmacopoeia Commission National Coordination Centre - PharmacovigilanceProgramme of India Ministry of Health and Family Welfare, Government of India. Accessed on 15 January 2018 Available:http://www.ipc.gov.in/PvPI/pub/Guidance%20Document%20for%20spontaneous%20Adverse%20Drug%20Reaction%20Reporting.pdf.
Christopher MR. The Role of Clinical Registries in Monitoring Drug Safety and Efficacy. Heart, LunCircul. 2015;24(11):1049–52. Available:http://dx.doi.org/10.1016/j.hlc.2015.04.184
Adusumilli PK, Parthasarathi G, Mothi SN, Sudheer PV, Swamy VHT. Evaluation of direct cost incurred for the management of adverse drug reactions (ADRs) to highly active antiretroviral therapy (HAART) in human immunodeficiency virus (HIV) positive patients. J of Pharm Res. 2015;64. DOI: 10.18579/jpcrkc/2015/0/0/79248.
Gyllensten H, Rehnberg C, Jönsson AK, Petzold M, Carlsten A, Andersson SK. Cost of illness of patient-reported adverse drug events: a population-based cross-sectional survey. BMJ Open. 2013;3(6):e002574. Available:http://doi.10.1136/bmjopen-2013002574
Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. Br J ClinPharmacol. 1998;45(3):301-08. DOI:10.1046/j.1365-2125.1998.00667.x
Qing-ping S, Xiao-dong J, Feng D, Yan L, Mei-ling Y, Jin-xiu Z, et al. Consequences, measurement, and evaluation of the costs associated with adverse drug reactions among hospitalized patients in China. BMC Health Servi Res. 2014;14(73). DOI:10.1186/1472-6963-14-73
Adhikari A, Bhattacharjee N, Bhattacharya S, Indu R, Ray M. Evaluation of Adverse Drug Reactions in Tertiary Care Hospital of Kolkata, West Bengal, India. J Young Pharm. 2017;9(3):311-14. DOI: 10.5530/jyp.2017.9.62
Sen M, Singh A, Misra M. Retrospective analysis of adverse drug reactions reported at ADR monitoring centre under PvPI in a tertiary care hospital. Int J Basic ClinPharmacol. 2018;7(3):303- 08. Available:http://dx.doi.org/10.18203/2319-2003.ijbcp20180103
Singh S, Gupta SK, Arya S, Sharma DK, Aggarwal V. Adverse Drug Reaction policy in a tertiary care hospital. Int J Res Foundation Hosp Health Adm. 2015;3(1)41-7.
Padmavathi S, Manimekalai K, Ambujam S. Causality, severity and preventability assessment of adverse cutaneous drug reaction: a prospective observational study in a tertiary care hospital. J clindiag res. 2013;7(12):2765–67. Available:http://doi.10.7860/JCDR/2013/7430.3753.
Asawari R, Arundhati D, Chintan P, Palak P, Atmaram P. Incidence, Severity and financial burden associated with adverse drug reactions in medicine inpatients. Asian J Pharm Clin Res. 2011;4:103- 11.
Srinivasan R, Ramya G. Adverse Drug Reaction-Causality Assessment. IJRPC.2011;1(3):606-12
Perrone V, Conti V, Venegoni M, Scotto S, DegliEsposti L, Sangiorgi D, et al. Seriousness, preventability, and burden impact of reported adverse drug reactions in Lombardy emergency departments: a retrospective 2-year characterization. Clinicoecon Outcomes Res. 2014;6:505-14. Available:https://doi.org/10.2147/CEOR.S71301. PMID: 25506231
Performance appraisal-District Economic Scenario 2017-18, Governmentof Andhra Pradesh. Directorate of Economics and statistics planning Department, Govt. of Andhra Pradesh: 159-168. Accessed on: 24 January 2019 Available:https://core.ap.gov.in/CMDashBoard/Download/Publications/DDP/final-DDP-2017 18.pdf
Chan ALF, Lee HY, Ho CH, Cham TM, Lin SJ. Cost evaluation of adverse drug reactions in hospitalized patients in Taiwan: a prospective, descriptive, observational study. Cur Ther Res. 2008;69(2):118-29. Available:http://dx.doi.org/10.1016/j.curtheres.2008.04.003.
Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J PharmacolPharmacother. 2013;4(1):73–7. Available:http://dx.doi.org/10.4103/0976-500X.120957.